US FDA has recently recognised a new drug called WELIREG also called as Belzutifan to treat patients with renal cell carcinoma.
It is produced by German based pharmaceutical company Merck.
Renal cell carcinoma is a disease in which cancer cells are found in the lining of very small tubes in the kidney.
Welireg’s approval is based on data from a late-stage trial, where the drug showed statistically significant and clinically meaningful improvement in progression-free survival (PFS) of patient compared to Novartis’ drug, everolimus.
Profession Free Survival (PFS) refers to how long a patient lives without the disease getting worse after treatment.
Leave a Reply